In This Section
Case Study
Find out how inVentiv helps a large pharma company regain lost ground for a product that has been on the market for three years.
Management Team
inVentiv Advance Insights, a subdivision of inVentiv Commercial, is led by a seasoned team of healthcare strategists with deep experience guiding pharmaceutical and biotech companies in commercialization planning and execution.

Sam Malik
Executive Vice President, Managed Markets
Sam Malik is the Executive Vice President of Managed Markets within inVentiv Advance Insights, where he leads and advises a diverse range of client engagements including market penetration strategies, life cycle management, product pricing, and portfolio management. He works closely with client stakeholders across functions including business development, marketing, sales and the executive suite. Recently he has developed launch and market entry strategies for new injectable biologics as well as market sizing and feasibility studies for new therapies.
Prior to his current position, Mr. Malik co-founded and was the managing partner Strategyx, a leading pharmaceutical and biotech strategy consulting company that was acquired by inVentiv Health in 2006.
Prior to Strategyx, Mr. Malik had a successful career in the pharmaceutical industry, holding senior positions in product marketing, market research account management, pricing and business development. He initiated the managed healthcare marketing function at sanofi-aventis at a time when seminal developments were shaping managed care's relationship with manufacturers. He created contract pricing models that are widely used in the industry today.
Mr. Malik holds an M.B.A. from the Amos Tuck School at Dartmouth.

Grace Duffy
Executive Vice President, Integrated Client Development
As Executive Vice President, Integrated Client Development, Grace Duffy is responsible for business development for inVentiv Advance Insights. Before assuming her current role, Ms. Duffy was a founder and executive partner of Strategyx, a leading pharmaceutical and biotech strategy consulting company that was acquired by inVentiv Health in 2006.
Throughout her career, Ms. Duffy has provided management consulting services in corporate strategies, brand management and business process re-engineering. She has assisted clients in building innovative pre-launch and post-launch programs, aligning organizational product and customer strategies and development of value propositions for the healthcare sector.
Ms. Duffy's prior experience includes a series of staff and management positions at a leading pharmaceutical company and serving as President of GDD Enterprises, a pharmaceutical business development consulting firm. She has worked in all facets of the healthcare and biopharmaceutical industries from medical research, to sales and marketing, to corporate strategy development.
Ms. Duffy earned her M.B.A in Pharmaceutical Marketing from Farleigh Dickenson University and her B.S. from Rutgers University.

Rebecca Hyde
Executive Vice President, Global Commercialization
Rebecca Hyde serves as Executive Vice President, Global Commercialization for inVentiv Advance Insights, where she is responsible for new product planning, brand management and commercialization consulting.
Ms. Hyde has accumulated twenty-five years experience in the pharmaceuticals and high technology industries. Her broad, cross-functional experience includes international marketing, payer marketing, product development, clinical development, strategic planning, research, sales and corporate staff.
Prior to joining inVentiv, Ms. Hyde was a partner with Strategyx, a leading pharmaceutical and biotech strategy consulting company that was acquired by inVentiv Health in 2006. At Strategyx, she was responsible for the development of a biotechnology and specialty practice – building organizational access and reimbursement experience in this complex area.
Prior to Strategyx, Ms. Hyde was CEO of a healthcare decision support software provider and Senior Director, Global Project Leader with Hoechst Marion Roussel, responsible for establishing the scientific, financial and commercial strategies for neuroscience products, and leading teams in the U.S., Europe and Japan, responsible for the implementation of those strategies.
She holds an undergraduate degree in Chemical Engineering and has continued to pursue her business management studies at institutions such as INSEAD, University of Michigan and Princeton.
